AU2019374812B2 - Pyridazinone compounds and uses thereof - Google Patents
Pyridazinone compounds and uses thereof Download PDFInfo
- Publication number
- AU2019374812B2 AU2019374812B2 AU2019374812A AU2019374812A AU2019374812B2 AU 2019374812 B2 AU2019374812 B2 AU 2019374812B2 AU 2019374812 A AU2019374812 A AU 2019374812A AU 2019374812 A AU2019374812 A AU 2019374812A AU 2019374812 B2 AU2019374812 B2 AU 2019374812B2
- Authority
- AU
- Australia
- Prior art keywords
- independently selected
- optionally substituted
- halogen
- rio
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756552P | 2018-11-06 | 2018-11-06 | |
| US62/756,552 | 2018-11-06 | ||
| PCT/US2019/060148 WO2020097258A1 (en) | 2018-11-06 | 2019-11-06 | Pyridazinone compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019374812A1 AU2019374812A1 (en) | 2021-06-10 |
| AU2019374812B2 true AU2019374812B2 (en) | 2025-03-06 |
Family
ID=69326619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019374812A Active AU2019374812B2 (en) | 2018-11-06 | 2019-11-06 | Pyridazinone compounds and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11390606B2 (https=) |
| EP (1) | EP3877367B1 (https=) |
| JP (2) | JP7671245B2 (https=) |
| CN (1) | CN113272280B (https=) |
| AU (1) | AU2019374812B2 (https=) |
| CA (1) | CA3118904A1 (https=) |
| WO (1) | WO2020097258A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019164852A1 (en) * | 2018-02-20 | 2019-08-29 | Edgewise Therapeutics, Inc. | Methods and compositions for treating movement disorders |
| CA3118908A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| DK3877376T3 (da) | 2018-11-06 | 2023-10-02 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
| AU2019374812B2 (en) | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| EP3914245A4 (en) | 2019-01-22 | 2022-08-24 | Aeovian Pharmaceuticals, Inc. | MTORC-1 MODULATORS AND USES THEREOF |
| EP4149621B1 (en) * | 2020-05-13 | 2024-10-30 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| WO2021231565A1 (en) * | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| EP4149465A1 (en) * | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| EP4149466A1 (en) * | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| EP4149467A1 (en) * | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| CN120302976A (zh) | 2022-09-09 | 2025-07-11 | 艾知怀斯治疗学公司 | 用于治疗神经肌肉病状的哒嗪酮组合物 |
| KR20250121977A (ko) * | 2023-01-04 | 2025-08-12 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | 피리다지논 헤테로사이클릭 화합물 Myosin II 억제제 및 이의 용도 |
| WO2025167826A1 (zh) * | 2024-02-06 | 2025-08-14 | 西藏海思科制药有限公司 | 三环化合物作为Myosin II抑制剂及其用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060189621A1 (en) * | 2003-03-07 | 2006-08-24 | Seiichi Sato | Benzofuran derivative |
| WO2009006959A1 (de) * | 2007-07-12 | 2009-01-15 | Merck Patent Gmbh | Pyridazinonderivate |
| WO2014096965A2 (en) * | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| US20150376167A1 (en) * | 2013-02-07 | 2015-12-31 | Merck Patent Gmbh | Pyridazinone-amides derivatives |
| JP2025040270A (ja) * | 2023-09-11 | 2025-03-24 | 共同印刷株式会社 | 赤外線遮断性生地 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6140270A (ja) | 1984-08-01 | 1986-02-26 | Morishita Seiyaku Kk | ピリダジノン誘導体 |
| DD286354A5 (de) | 1989-08-08 | 1991-01-24 | Karl-Marx-Universitaet Leipzig,De | Verfahren zur herstellung substituierter 2-carbamoyl-methyl-4-phenyl-1,2,5,6-tetrahydro- und 1,2-dihydro-1-oxo-pyridazine |
| ES2131506T3 (es) | 1990-09-21 | 1999-08-01 | Rohm & Haas | Dihidropiridacinonas y piridacinonas como fungicidas. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| IL118631A (en) | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| DE19629817A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| NZ522882A (en) | 2000-06-05 | 2004-07-30 | Altana Pharma Bv | Pyridazinone compounds effective as beta-2-adrenoreceptor agonists as well as PDE4-inhibitors |
| US20040067955A1 (en) | 2002-09-06 | 2004-04-08 | Fujisawa Pharmaceutical Co. Ltd. | Pyridazinone compound and pharmaceutical use thereof |
| JP4890439B2 (ja) | 2005-03-07 | 2012-03-07 | 杏林製薬株式会社 | ピラゾロピリジン−４−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 |
| WO2007044796A2 (en) | 2005-10-11 | 2007-04-19 | Nps Pharmaceuticals, Inc. | Pyridazinone compounds as calcilytics |
| DE102005057924A1 (de) | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| UA95644C2 (ru) | 2006-07-25 | 2011-08-25 | Сефалон, Инк. | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| DE102007025717A1 (de) * | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| DE102007025718A1 (de) * | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| DE102007038957A1 (de) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-Thioxo-pyridazinderivate |
| DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
| WO2009142732A2 (en) | 2008-05-20 | 2009-11-26 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| WO2012021707A2 (en) * | 2010-08-11 | 2012-02-16 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
| BR112013007499A2 (pt) | 2010-09-01 | 2016-07-12 | Genentech Inc | piridazinonas - métodos de criação e usos |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| WO2013057101A1 (de) | 2011-10-17 | 2013-04-25 | Bayer Intellectual Property Gmbh | Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer |
| CN103570730A (zh) | 2012-08-01 | 2014-02-12 | 中国科学院上海药物研究所 | 具有桥环结构的稠环哒嗪酮类化合物及其制备方法和用途 |
| US20140073634A1 (en) | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
| US9566310B2 (en) | 2012-09-10 | 2017-02-14 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno | Methods of treating muscular dystrophy |
| US9216180B2 (en) | 2012-10-02 | 2015-12-22 | New York University | Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay |
| MX365950B (es) | 2013-03-13 | 2019-06-19 | Flatley Discovery Lab Llc | Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica. |
| WO2014189634A1 (en) | 2013-04-19 | 2014-11-27 | University Of Iowa Research Foundation | Angiotensins in muscular dystrophy |
| US10555960B2 (en) | 2015-06-05 | 2020-02-11 | Ptc Therapeutics, Inc. | Use of an aminoglycoside for nonsense mutation suppression and the treatment of disease |
| JP7007199B2 (ja) | 2015-06-10 | 2022-02-10 | アソシアシオン・アンスティテュ・ドゥ・ミオロジー | デュシェンヌ型筋ジストロフィーのための併用療法 |
| CN106467495A (zh) * | 2015-08-19 | 2017-03-01 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及用途 |
| WO2017046117A1 (en) * | 2015-09-15 | 2017-03-23 | Abbvie Inc. | Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use |
| WO2018081378A1 (en) | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
| CA3041675A1 (en) | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
| AU2017348186A1 (en) | 2016-10-26 | 2019-05-16 | Proteostasis Therapeutics, Inc | Pyridazine derivatives, compositions and methods for modulating CFTR |
| EP3600322A1 (en) | 2017-03-28 | 2020-02-05 | Boehringer Ingelheim International GmbH | Nintedanib for use in methods for the treatment of muscular dystrophy |
| TWI902102B (zh) | 2017-04-06 | 2025-10-21 | 美商富曼西公司 | 殺真菌之噁二唑 |
| US20180303821A1 (en) | 2017-04-24 | 2018-10-25 | BraneQuest, Inc. | Membrane active molecules |
| BE1025518B1 (fr) | 2017-08-30 | 2019-04-03 | E2 Drives Sa | Groupe motopropulseur |
| EP3700516B1 (en) | 2017-10-27 | 2024-01-24 | Sonic Master Limited | Inhibitors of dux4 induction for regulation of muscle function |
| CN112166181B (zh) | 2018-05-17 | 2024-03-08 | 保尔特纺织品公司 | 用于改善重组蛋白分泌的sec经修饰菌株 |
| EP4685140A1 (en) | 2018-06-04 | 2026-01-28 | Ohio State Innovation Foundation | Eaat2 activators and methods of using thereof |
| EP3828174A4 (en) | 2018-07-19 | 2022-08-17 | Sumitomo Pharma Co., Ltd. | PYRIDAZINONE DERIVATIVE |
| CN108947912B (zh) | 2018-07-31 | 2021-10-01 | 中国人民解放军总医院 | 一种靶向Neddylation通路的抗肿瘤化合物 |
| CA3118908A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| AU2019374812B2 (en) | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| DK3877376T3 (da) | 2018-11-06 | 2023-10-02 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
| EP4149621B1 (en) | 2020-05-13 | 2024-10-30 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| WO2021231565A1 (en) | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| EP4149465A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| EP4149467A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| EP4149466A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| JP7694135B2 (ja) | 2021-05-11 | 2025-06-18 | 株式会社大林組 | 接続構造及び接続方法 |
| EP4433473A1 (en) | 2021-11-17 | 2024-09-25 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CN119317621A (zh) | 2022-05-11 | 2025-01-14 | 艾知怀斯治疗学公司 | 制备哒嗪酮化合物的方法 |
| CN120302976A (zh) | 2022-09-09 | 2025-07-11 | 艾知怀斯治疗学公司 | 用于治疗神经肌肉病状的哒嗪酮组合物 |
-
2019
- 2019-11-06 AU AU2019374812A patent/AU2019374812B2/en active Active
- 2019-11-06 JP JP2021524226A patent/JP7671245B2/ja active Active
- 2019-11-06 CN CN201980088112.8A patent/CN113272280B/zh active Active
- 2019-11-06 CA CA3118904A patent/CA3118904A1/en active Pending
- 2019-11-06 EP EP19842909.4A patent/EP3877367B1/en active Active
- 2019-11-06 WO PCT/US2019/060148 patent/WO2020097258A1/en not_active Ceased
-
2020
- 2020-11-03 US US17/088,468 patent/US11390606B2/en active Active
-
2022
- 2022-05-27 US US17/827,547 patent/US12240833B2/en active Active
-
2024
- 2024-12-23 JP JP2024226318A patent/JP2025041790A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060189621A1 (en) * | 2003-03-07 | 2006-08-24 | Seiichi Sato | Benzofuran derivative |
| WO2009006959A1 (de) * | 2007-07-12 | 2009-01-15 | Merck Patent Gmbh | Pyridazinonderivate |
| WO2014096965A2 (en) * | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| US20150376167A1 (en) * | 2013-02-07 | 2015-12-31 | Merck Patent Gmbh | Pyridazinone-amides derivatives |
| JP2025040270A (ja) * | 2023-09-11 | 2025-03-24 | 共同印刷株式会社 | 赤外線遮断性生地 |
Non-Patent Citations (18)
| Title |
|---|
| CAS registry number: 922866-23-7; Date entered STN: 23 Feb 2007; 2-[(4-fluorophenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 922866-82-8; Date entered STN: 23 Feb 2007; Chemical name: 2-[(2,5-dimethylphenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 922867-00-3: Date entered STN: 23 Feb 2007; Chemical name: 2-[(2,4-dichlorophenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 922867-06-9; Date entered STN: 23 Feb 2007; Chemical name: 2-[(3,4-dichlorophenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 922935-15-7; Date entered STN: 23 Feb 2007; Chemical name: 2-[(3-fluorophenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 922935-69-1; Date entered STN: 23 Feb 2007; Chemical name: 2-[(2-methylphenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 922935-77-1; Date entered STN: 23 Feb 2007; Chemical name: 6-[4-(1-piperidinyl)phenyl]-2-[[3-(trifluoromethyl)phenyl]methyl]-3(2H)-pyridazinone * |
| CAS registry number: 922935-98-6; Date entered STN: 23 Feb 2007; Chemical name: 2-[(4-chlorophenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 922980-68-5; Date entered STN: 23 Feb 2007; Chemical name: 2-[(2-fluorophenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 922981-23-5; Date entered STN: 23 Feb 2007; Chemical name: 2-[(3-nitrophenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 922981-25-7; Date entered STN: 23 Feb 2007; Chemical name: 6-[4-(1-piperidinyl)phenyl]-2-[[4-(trifluoromethyl)phenyl]methyl]-3(2H)-pyridazinone * |
| CAS registry number: 922981-41-7; Date entered STN: 23 Feb 2007; Chemical name: 2-[(2-chlorophenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 922981-44-0; Date entered STN: 23 Feb 2007; Chemical name: 2-[(3-chlorophenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 923063-37-0; Date entered STN: 26 Feb 2007; Chemical name: 2-[(3-methylphenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 923063-76-7; Date entered STN: 26 Feb 2007; Chemical name: 2-[(4-methylphenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 923063-82-5; Date entered STN: 26 Feb 2007; Chemical name: 2-[(4-bromophenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 923063-90-5; Date entered STN: 26 Feb 2007; Chemical name: 2-[(4-nitrophenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
| CAS registry number: 923063-98-3; Date entered STN: 26 Feb 2007; Chemical name: 2-[(2-chloro-6-fluorophenyl)methyl]-6-[4-(1-piperidinyl)phenyl]-3(2H)-pyridazinone * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019374812A1 (en) | 2021-06-10 |
| US11390606B2 (en) | 2022-07-19 |
| US12240833B2 (en) | 2025-03-04 |
| JP2022506686A (ja) | 2022-01-17 |
| US20230048816A1 (en) | 2023-02-16 |
| CN113272280B (zh) | 2026-01-09 |
| CA3118904A1 (en) | 2020-05-14 |
| EP3877367A1 (en) | 2021-09-15 |
| EP3877367B1 (en) | 2024-05-22 |
| JP2025041790A (ja) | 2025-03-26 |
| JP7671245B2 (ja) | 2025-05-01 |
| WO2020097258A1 (en) | 2020-05-14 |
| CN113272280A (zh) | 2021-08-17 |
| US20210130327A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019374812B2 (en) | Pyridazinone compounds and uses thereof | |
| JP7357135B2 (ja) | ピリダジノン化合物およびその使用 | |
| JP7429750B2 (ja) | ピリダジノン化合物およびその使用 | |
| US20230338375A1 (en) | Substituted pyridazinones for use in the treatment of neuromuscular diseases | |
| EP4149621B1 (en) | Pyridazinone compounds for the treatment of neuromuscular diseases | |
| EP4149465A1 (en) | Substituted pyridazinone for use in the treatment of neuromuscular diseases | |
| EP4149467A1 (en) | Substituted pyridazinone for use in the treatment of neuromuscular diseases | |
| HK40091925A (en) | Pyridazinone compounds and uses thereof | |
| HK40057655A (en) | Pyridazinone compounds and uses thereof | |
| HK40057655B (en) | Pyridazinone compounds and uses thereof | |
| EA050889B1 (ru) | Соединения пиридазинонов и их применения | |
| EA049463B1 (ru) | Соединения пиридазинонов и их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |